Mon, March 5, 2018
Fri, March 2, 2018
Thu, March 1, 2018

Alethia Young Maintained (BMRN) at Buy with Increased Target to $116 on, Mar 2nd, 2018

Alethia Young of Credit Suisse, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $113 to $116 on, Mar 2nd, 2018.

Alethia has made no other calls on BMRN in the last 4 months.



There are 7 other peers that have a rating on BMRN. Out of the 7 peers that are also analyzing BMRN, 0 agree with Alethia's Rating of Hold.



These are the ratings of the 7 analyists that currently disagree with Alethia


  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $124 on, Friday, February 23rd, 2018
  • Joseph Schwartz of "Leerink Swann" Maintained at Buy with Decreased Target to $132 on, Friday, February 23rd, 2018
  • M. Ian Somaiya of "BMO Capital" Maintained at Buy with Increased Target to $125 on, Friday, February 23rd, 2018
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $112 on, Friday, February 23rd, 2018
  • Stephen Willey of "Stifel" Maintained at Strong Buy with Decreased Target to $102 on, Friday, February 23rd, 2018
  • Cory Kasimov of "JP Morgan" Maintained at Buy with Decreased Target to $129 on, Wednesday, January 24th, 2018
  • Liana Moussatos of "Wedbush" Upgraded from Hold to Buy on, Thursday, December 14th, 2017